Steadybase.

Zai Lab Ltd.

Website LinkedIn Latest 10-K
  • ZLAB ยท Nasdaq
  • Pharmaceutical Preparations
  • Shanghai, China
  • 1,784 employees
  • CIK 0001704292

Updated from SEC filings through

Top things to know

Executives

What leadership is saying

“We are approaching a defining period for Zai Lab, as we advance toward bringing our first internally developed innovative medicines to patients globally”

Dr. Samantha Du, Founder, Chairperson and Chief Executive Officer of Zai Lab
Earnings press release (8-K Ex. 99.1), filed November 5, 2026

Zai Lab Ltd is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Shanghai, China. It trades as ZLAB on Nasdaq. Revenue was $460M in the fiscal year ending December 31, 2025, +15.3% from the year before. It reported about 1,784 employees. Ying Du is Chairperson & CEO.

Five-year financials

MetricFY2025FY2024FY2023FY2022FY2021
Revenue $460M
10-K, 2026-02-26
$399M
10-K, 2026-02-26
$267M
10-K, 2026-02-26
$215M
10-K, 2025-02-27
$144M
10-K, 2024-02-27
Operating income -$229M
10-K, 2026-02-26
-$282M
10-K, 2026-02-26
-$367M
10-K, 2026-02-26
-$404M
10-K, 2025-02-27
-$700M
10-K, 2024-02-27
SG&A $278M
10-K, 2026-02-26
$299M
10-K, 2026-02-26
$282M
10-K, 2026-02-26
$259M
10-K, 2025-02-27
$219M
10-K, 2024-02-27
Net income -$176M
10-K, 2026-02-26
-$257M
10-K, 2026-02-26
-$335M
10-K, 2026-02-26
-$443M
10-K, 2025-02-27
-$704M
10-K, 2024-02-27

Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.

Leadership and board

NameTitleSource
Ying Du Chairperson & CEO Form 4, July 6, 2026
Samantha (Ying) Du Board member (per proxy)
bio: Founder, Chairperson of the Board of Directors, and Chief Executive Officer
DEF 14A, April 28, 2026
Yajing Chen Chief Financial Officer Form 4, August 21, 2026
Frazor Titus Edmondson III Chief Legal Officer Form 4, June 29, 2026
F. Ty Edmondson Named in proxy
bio: Chief Legal Officer and Corporate Secretary
DEF 14A, April 28, 2026
Rafael G. Amado Named in proxy
bio: President, Head of Global Research and Development
DEF 14A, April 28, 2026
Yizhe Wang Operating Partner Form 4, June 8, 2026
John David Diekman Board member (per proxy)
bio: Lead Independent Director
DEF 14A, April 28, 2026
Nisa Bernice Wing-Yu Leung Board member (per proxy)
bio: Independent Director
DEF 14A, April 28, 2026
Richard Brian Gaynor Board member (per proxy)
bio: Independent Director
DEF 14A, April 28, 2026

What Zai Lab Ltd does

We are a patient-focused, innovative, commercial-stage, global biopharmaceutical company with a substantial presence in both Greater China and the United States. We are focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. We intend to leverage our competencies and resources to positively impact human health.

Item 1. Business, 10-K for the year ending December 31, 2025

Shares and governance

Shares outstanding 88.6 million (as of February 26, 2021) 10-K, March 1, 2021
Public float $3.8B (as of June 30, 2025) 10-K, February 26, 2026
Reportable segments 1 (period ending September 30, 2026) 10-Q, November 5, 2026
Latest proxy statement Meeting June 17, 2026 (filed April 28, 2026) DEF 14A, April 28, 2026
Auditor Kpmg LLP (Short Hills, New Jersey) Latest 10-K

Insider trades

Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.

DateInsiderTradeSharesValueSource
November 10, 2026 Richard Gaynor
Director
Buy 1,228 $33K Form 4, November 13, 2026
August 19, 2026 Yajing Chen
Chief Financial Officer
Sale 260 $7K Form 4, August 21, 2026
August 12, 2026 William Lis
Director
Sale 8,506 $213K Form 4, August 13, 2026
August 11, 2026 Yajing Chen
Chief Financial Officer
Sale 619 $15K Form 4, August 13, 2026
July 1, 2026 Richard Gaynor
Director
Buy 1,736 $33K Form 4, July 6, 2026
June 30, 2026 Ying Du
Chairperson & CEO
Sale 7,026 $130K Form 4, July 1, 2026
June 26, 2026 Frazor Titus Edmondson III
Chief Legal Officer
Sale 4,103 $72K Form 4, June 29, 2026
June 26, 2026 Ying Du
Chairperson & CEO
Sale 24,543 $429K Form 4, June 29, 2026

Recent 8-K events

  • 8-K filed 2026-11-05
    • Item 2.02 Results of operations and financial condition (earnings release)
  • 8-K filed 2026-10-23
    • Item 1.01 Entry into a material definitive agreement
    • Item 3.02 Unregistered sales of equity securities
    • Item 7.01 Regulation FD disclosure
    • Item 8.01 Other events
  • 8-K filed 2026-08-06
    • Item 2.02 Results of operations and financial condition (earnings release)
  • 8-K filed 2026-06-17
    • Item 5.07 Submission of matters to a vote of security holders
  • 8-K filed 2026-05-21
    • Item 5.02 Departure or appointment of directors or officers; compensation
  • 8-K filed 2026-05-07
    • Item 2.02 Results of operations and financial condition (earnings release)
  • 8-K filed 2026-02-26
    • Item 2.02 Results of operations and financial condition (earnings release)
  • 8-K filed 2025-11-06
    • Item 2.02 Results of operations and financial condition (earnings release)
  • 8-K filed 2025-10-16
    • Item 1.01 Entry into a material definitive agreement
    • Item 2.03 Creation of a direct financial obligation
  • 8-K filed 2025-08-07
    • Item 2.02 Results of operations and financial condition (earnings release)

Frequently asked questions about Zai Lab Ltd

What does Zai Lab Ltd do?
In its own words, from Item 1 of its 10-K: "We are a patient-focused, innovative, commercial-stage, global biopharmaceutical company with a substantial presence in both Greater China and the United States. We are focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. We intend to leverage our competencies and resources to positively impact human health."
What is Zai Lab Ltd's revenue?
$460M for the fiscal year ending December 31, 2025, from its 10-K filed February 26, 2026.
Is Zai Lab Ltd profitable?
Zai Lab Ltd reported net income of -$176M for the fiscal year ending December 31, 2025.
How many employees does Zai Lab Ltd have?
About 1,784 as of December 31, 2025, as stated in its annual report.
Who is the CEO of Zai Lab Ltd?
Ying Du, Chairperson & CEO, as named in a 4 filed July 6, 2026.
Who is the CFO of Zai Lab Ltd?
Yajing Chen, Chief Financial Officer, as named in a 4 filed August 21, 2026.
Where is Zai Lab Ltd headquartered?
Shanghai, China.
What is Zai Lab Ltd's stock ticker?
ZLAB on Nasdaq.
What industry is Zai Lab Ltd in?
Pharmaceutical Preparations, SIC code 2834.
What is Zai Lab Ltd's website?
zailaboratory.com.
When does Zai Lab Ltd report earnings next?
February 4, 2027. Source: estimate_8k_pattern.
Is Zai Lab Ltd a public company?
Yes. Zai Lab Ltd files with the SEC under CIK 0001704292 and trades as ZLAB.
Who audits Zai Lab Ltd?
Kpmg LLP, Short Hills, New Jersey, as named in its latest annual report (10-K).
How many shares of Zai Lab Ltd are outstanding?
88.6 million shares as of February 26, 2021, from its 10-K filed March 1, 2021.
What is Zai Lab Ltd's public float?
$3.8B as of June 30, 2025, as reported on the cover of its 10-K filed February 26, 2026.
How many business segments does Zai Lab Ltd report?
1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 5, 2026.
When is Zai Lab Ltd's annual shareholder meeting?
June 17, 2026, per its proxy statement (DEF 14A) filed April 28, 2026.
Have Zai Lab Ltd insiders traded stock recently?
Since June 30, 2025, officers and directors reported 44 open-market sales worth about $19.1M and 4 purchases worth about $388K on Forms 4 and 5. The most recent: Richard Gaynor (Director) bought 1,228 shares on November 10, 2026.